Action Pharma A/S is a biopharmaceutical company founded in 2000 and located in Denmark
Our main strategy is to bring drug candidates rapidly from pre-clinical development into clinical trials for subsequent partnering.
September 26, 2011
Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery demonstrates positive top-line results
Read more
August 8, 2011
Last patient completes last visit in Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery
Read more
May 9, 2011
Action Pharma completes dosing in phase IIb clinical trial with AP214
Read more
September 13, 2010
Action Pharma obtains positive phase II results with AP214
Read more
June 07, 2010
Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214
Read more
June 03, 2010
Action Pharma completes EUR 5 million financing round to advance its lead project AP214
Read more
March 29, 2010
Action Pharma completes dosing in phase II clinical trial with AP214 to prevent acute kidney injury associated with cardiac surgery
Read more